[go: up one dir, main page]

HK1220367A1 - 人类受试者中的肌抑素拮抗作用 - Google Patents

人类受试者中的肌抑素拮抗作用 Download PDF

Info

Publication number
HK1220367A1
HK1220367A1 HK16108415.2A HK16108415A HK1220367A1 HK 1220367 A1 HK1220367 A1 HK 1220367A1 HK 16108415 A HK16108415 A HK 16108415A HK 1220367 A1 HK1220367 A1 HK 1220367A1
Authority
HK
Hong Kong
Prior art keywords
human subjects
myostatin
peptibody
antagonism
myostatin antagonist
Prior art date
Application number
HK16108415.2A
Other languages
English (en)
Inventor
Desmond Padhi Ian
Han Huiquan
Michael Haqq Christopher
Ciechanover Isaac
Original Assignee
Amgen Inc.
Pinta Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Pinta Biotherapeutics, Inc. filed Critical Amgen Inc.
Publication of HK1220367A1 publication Critical patent/HK1220367A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
HK16108415.2A 2013-03-15 2014-03-14 人类受试者中的肌抑素拮抗作用 HK1220367A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799928P 2013-03-15 2013-03-15
US201361799928P 2013-03-15
PCT/US2014/029502 WO2014144903A1 (en) 2013-03-15 2014-03-14 Myostatin antagonism in human subjects

Publications (1)

Publication Number Publication Date
HK1220367A1 true HK1220367A1 (zh) 2017-05-05

Family

ID=51537829

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108415.2A HK1220367A1 (zh) 2013-03-15 2014-03-14 人类受试者中的肌抑素拮抗作用

Country Status (15)

Country Link
US (1) US20160038588A1 (zh)
EP (1) EP2968463A4 (zh)
JP (1) JP2016516064A (zh)
KR (1) KR20150140294A (zh)
CN (1) CN105530949A (zh)
AU (1) AU2014228423A1 (zh)
CA (1) CA2906835A1 (zh)
CL (1) CL2015002691A1 (zh)
EA (1) EA201591825A1 (zh)
HK (1) HK1220367A1 (zh)
IL (1) IL241437A0 (zh)
MX (1) MX2015011430A (zh)
PH (1) PH12015502155A1 (zh)
SG (1) SG11201507413XA (zh)
WO (1) WO2014144903A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
MX2011013898A (es) 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
US8940878B2 (en) 2009-06-25 2015-01-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014030728A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 FcγRIIb特異的Fc領域改変体
EP2970484B2 (en) * 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
ES2770925T3 (es) 2015-03-23 2020-07-03 Aqua Products Inc Limpiador de piscinas robótico autopropulsado con conjunto de lavado a presión para levantar residuos de una superficie por debajo del limpiador de piscinas
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
CN112601538B (zh) 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法
EP3569614A1 (en) * 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1797127T3 (en) * 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
MX2008007324A (es) * 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TWI573802B (zh) * 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
WO2011040823A1 (en) * 2009-10-01 2011-04-07 Covita Limited Synthetic myostatin peptide antagonists
TW201601741A (zh) * 2013-09-09 2016-01-16 品特生物療法有限公司 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑

Also Published As

Publication number Publication date
CN105530949A (zh) 2016-04-27
US20160038588A1 (en) 2016-02-11
MX2015011430A (es) 2016-04-20
KR20150140294A (ko) 2015-12-15
CA2906835A1 (en) 2014-09-18
SG11201507413XA (en) 2015-10-29
JP2016516064A (ja) 2016-06-02
IL241437A0 (en) 2015-11-30
EP2968463A1 (en) 2016-01-20
WO2014144903A1 (en) 2014-09-18
AU2014228423A1 (en) 2015-11-05
PH12015502155A1 (en) 2016-01-25
EP2968463A4 (en) 2016-11-23
CL2015002691A1 (es) 2016-04-29
EA201591825A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
HK1220367A1 (zh) 人类受试者中的肌抑素拮抗作用
WO2012045090A3 (en) Therapeutic use of a tlr agonist and combination therapy
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2015009726A3 (en) Medical uses of cd38 agonists
HK1221144A1 (zh) 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
ZA201705874B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
CA2908957C (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
PH12017500392A1 (en) Medical treatments based on anamorelin
EP3015111A4 (en) Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
WO2013110030A3 (en) Vaccines against antigens involved in therapy resistance and methods of using same
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
WO2013176877A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EP2961424A4 (en) ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER
MX2018000287A (es) Dispositivo de electroestimulacion.
IT1397473B1 (it) Apparecchio portatile di elettrostimolazione del corpo umano
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
HK1233917A1 (zh) 使用 tor 激酶抑制剂联合疗法治疗癌症的方法